Access a selected list of preclinical and clinical study bibliographies for each strain
- Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007;45: 454-460.
- Hibberd AA, Yde CC, Ziegler ML, et al. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Beneficial Microbes. 2019;10(2):121-135.
- Klein A, Friedrich U, Vogelsang H, Jahreis G. Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC B-420 modulate unspecific cellular immune response in healthy adults. Eur J Clin Nutr. 2008;62:584-659.
- Kok RG, de Waal A, Schut F, et al. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl Environ Microbiol. 1996;62:3668-3672.
- Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152:552-558.
- Mokkala K, Laitinen K, Roytio H. Bifidobacterium lactis B-420 and fish oil enhance intestinal epithelial integrity in Caco-2 cells. Nutr Res. 2016;36:246-252.
- Putaala H, Salusjarvi T, Nordstrom M, et al. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol. 2008;159;692-698.
- Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults—Randomized controlled trial. EBioMedicine. 2016.Nov;13:190–200. http://dx.doi.org/10.1016/j.ebiom.2016.10.036.
- Stenman LK, Waget A, Garret C, et al. Potential probiotic Bifidobacterium animalis ssp. lactis B-420 prevents weight gain and glucose intolerance in diet-induced obese mice. Beneficial Microbes. 2014;5:437-445.
- Stenman LK, Waget A, Garret C, et al. Probiotic BB-420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. Diabetology & Metabolic Syndrome. 2015;7:75.
- De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta® complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–867.
- Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018;298(1):139-145.
- Russo R, Superti F, Karadja E, De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes. 2019;10(1):19-26.
- Russo R, Superti F, Karadja E, De Seta F. Randomised clinical trial in women with recurrent vulvovaginal candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2018;62(4):328-335.
- Slykerman RF, Hood F, Wickens K, et al. Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: A randomized double-blind placebo-controlled trial. EBioMedicine. 2017;24:159-165.
- Wickens K, Barthow C, Mitchell EA, et al. Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years. Pediatr Allergy Immunol. 2018 Dec;29(8):808-814. doi: 10.1111/pai.12982.
- Wickens K, Barthow C, Mitchell EA, et al. Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema. Pediatr Allergy Immunol. 2018;29(3);296-302. doi:10.1111/pai.12874.
- Wickens K, Black P, Stanley TV, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2008;122(4):788-794.
- Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42(7):1071-1079.
- Wickens K, Stanley TV, Mitchell EA, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy. 2013;43(9):1048-57.
- Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017;117:804-813
- Bertuccini L, Russo R, Iosi F, Superti F. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. Intl J Immunopathology Pharmacology. 2017;30(2):163-167.
- De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta® complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–867.
- Elawadli I, Brisbin JT, Mallard BA, et al. Differential effects of lactobacilli on activation and maturation of mouse dendritic cells. Beneficial Microbes. 2014;5(3):323-334.
- Jang SE, Jeong JJ, Choi SY, et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 attenuate gardnerella vaginalis-infected bacterial vaginosis in mice. Nutrients. 2017;9:531; doi:10.3390/nu9060531.
- Paineau D, Carcano D, Leyer G. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107-113.
- Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018;298(1):139-145.
- Russo R, Superti F, Karadja E, De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes. 2019;10(1):19-26.
- Russo R, Superti F, Karadja E, De Seta F. Randomised clinical trial in women with recurrent vulvovaginal candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2018;62(4):328-335.
- Dalziel JE, Anderson RC, Peters JS, et al. Promotility action of the probiotic Bifidobacterium lactis HN019 extract compared with prucalopride in isolated rat large intestine. Frontiers in Neuroscience. 2017;11.
- Gopal PK, Prasad J, Gill HS. Effects of the consumption of Bifidobacterium lactis HN019 (DR10 TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutrition Research. 2003;23:1313-1328.
- Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp.lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled and dose-ranging trial. Gut Microbes. 2017; Dec 11:0.
- Miller LE, Lehtoranta L, Lehtinen MJ. The Effect of Bifidobacterium animalis ssp. lactis HN019 on cellular immune function in healthy elderly subjects: systematic review and meta-analysis. Nutrients. 2017;9:191.
- Prasad J, Sazawal S, Dhingra U, Gopal PK. Detection of viable Bifidobacterium lactis HN019 (DR10TM) in stools of children during a synbiotic dietary intervention trial. Intl Dairy J. 2013;30:64-67.
- Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019™ on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064.
- Wickens K, Black PN, Stanley TV, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clinical Immunology. 2008;122:788-794.
- Bartosch S, Woodmansey EJ, Paterson JC, McMurdo ME, Macfarlane GT. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis. 2005;40:28-37.
- Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
- Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC (2009). Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124(2):172-179.
- Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
- Ouwehand AC, Nermes M, Collado MC, et al. Specific probiotics alleviate allergic rhinitis during the birch pollen season. World J Gastroenterology. 2009;15.
- Turner RB, Woodfolk JA, Borish L, et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial. Benef Microbes. 2017;8(2):207-215.
- West NP, Horn PL, Pyne DB, et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33(4):581-587.
- Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010;104:1831-1838.
- Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
- Kleeman EG, Klaenhammer TR. Adherence of Lactobacillus species to human fetal intestinal cells. J Dairy Sci. 1982;65:2063-2069.
- Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124(2):172-179.
- Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
- Candela M, Bergmann S, Vici M, et al. Binding of human plasminogen to Bifidobacterium. J Bacteriol. 2007;189:5929-5936.
- Candela M, Biagi E, Centanni M, et al. Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host. Microbiology. 2009;155:3294-3303.
- Candela M, Fiori J, Dipalo S, et al. Rapid MALDI-TOF-MS analysis in the study of interaction between whole bacterial cells and human target molecules: Binding of Bifidobacterium to human plasminogen. J Microbiol Methods. 2008;73:276–278.
- Candela M, Miccoli G, Bergmann S, et al. Plasminogen dependent proteolytic activity in Bifidobacterium lactis. Microbiology. 2008;154:2457-2462.
- Candela M, Perna F, Carnevali P, et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol. 2008;125:286-292.
- Candela M, Seibold G, Vitali B, et al. Real-time PCR quantification of bacterial adhesion to Caco-2 cells: Competition between bifidobacterial and enteropathogens. Res Microbiol. 2005;156:887–895.
- Candela M, Turroni S, Centanni M, et al. Relevance of Bifidobacterium animalis subsp. lactis plasminogen binding activity in the human gastrointestinal microenvironment. Appl Environ Microbiol. 2011;77:7072-7076.
- Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
- Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124(2):172-179.
- Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
- Ding WK, Shah NP. Acid, bile and heat tolerance of free and microencapsulated probiotic bacteria. J Food Sci. 2007;72:M446-450.
- Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
- Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br J Nutr. 2005;93(Suppl. 1):S31-34.
- Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
- Patterson E, Griffin SM, Ibarra A, Ellsiepen E, Hellhammer J. Lacticaseibacillus paracasei Lpc-37® improves psychological and physiological markers of stress and anxiety in healthy adults: a randomized, double-blind, placebo-controlled and parallel clinical trial (the Sisu study). Neurobiol Stress. 2020;13:100277. doi: 10.1016/j.ynstr.2020.100277.
- Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
- Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
